BridgeBio Pharma BBIO Intangible Purchases
Intangible Purchases at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireIntangibleAssets.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's intangible purchases.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's intangible purchases?
- BridgeBio Pharma (BBIO) reported intangible purchases of $0 in Q1 2026.
- How has BridgeBio Pharma's intangible purchases changed year-over-year?
- BridgeBio Pharma's intangible purchases decreased by 100.0% year-over-year, from $1.6M to $0.
- What is the long-term trend for BridgeBio Pharma's intangible purchases?
- Over 4 years (2021 to 2025), BridgeBio Pharma's intangible purchases has grown at a -29.8% compound annual growth rate (CAGR), from $35M to $8.5M.
- What does intangible purchases mean?
- Cash spent to acquire intellectual property, patents, or software.
- How do you interpret intangible purchases?
- Higher spending indicates active investment in the company's long-term pipeline and competitive moat.
- How does intangible purchases compare across companies?
- Critical metric for R&D-heavy companies; peers often show significant investment in IP acquisition.